BioTissue Ocular Revenue
Biotechnology Research • 
7300 Corporate Center Dr, Suite 700, United States • 51-100 Employees
BioTissue Ocular revenue & valuation
| Annual revenue | $8,555,500 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $27,400,000 |
| Total funding | No funding |
Key Contacts at BioTissue Ocular
Matt Newsom
Regional Sales Director
Ben Moes
Regional Sales Director
Joelle Bordelon Graham
Regional Sales Director
Anela Park
Regional Sales Director - West
Eddie Shaldone
Regional Sales Director
Sterling Korona
Regional Sales Director
Sterling Korona
Regional Director
Nicholle Freireich
Director Of Sales
Company overview
| Headquarters | 7300 Corporate Center Dr, Suite 700, Miami, Florida 33126, US |
| Phone number | +17868176690 |
| Website | |
| NAICS | 541714 |
| Founded | 1997 |
| Employees | 51-100 |
| Socials |
BioTissue Ocular Email Formats
BioTissue Ocular uses 2 email formats. The most common is {first name}{last name} (e.g., johndoe@biotissue.com), used 82.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@biotissue.com | 82.4% |
{first initial}{last name} | jdoe@biotissue.com | 17.6% |
About BioTissue Ocular
BioTissue Holdings, Inc. is the pioneer and leader in regenerative medicine for ocular surface disease and injury, as well as ocular hygiene solutions for eye care professionals. Established in 1997, BioTissue serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis (CCH) also known as mechanical dry eye, pterygium and severe dry eye. Eye care professionals understand that good medicine is based on good science. BioTissue prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for the management of a range of ocular surface and lid margin diseases. BioTissue adheres to the FDA tissue and medical device guidelines. BioTissue offers the only commercially available amniotic membrane that preserves the native integrity, activity, and function exhibited by the tissue in utero for ocular surface wound repair and wound healing. Our proprietary processing and preservation method retains vital cytokines and growth factors which facilitate healing mechanisms such as: • Anti-inflammatory • Anti-scarring • Anti-angiogenic • Pain reduction • Promotion of epithelial healing
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
BioTissue Ocular has 72 employees across 9 departments.
Departments
Number of employees
Funding Data
BioTissue Ocular has never raised funding before.
Finland
Canada
New Zealand
United Kingdom
Netherlands
Taiwan, Province of ChinaFrequently asked questions
4.8
40,000 users
